Is Quince Therapeutics, Inc. (QNCX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 260.0% / 30% | 716.0% / 30% | 15.5% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 260.0% / 33% | 716.0% / 33% | 15.5% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 12.9% / 33% | 35.6% / 33% | 0.8% / 33% | N/A | ✗ NOT HALAL |
| S&P | 260.0% / 33% | 716.0% / 33% | 15.5% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 12.9% / 33% | 35.6% / 33% | 0.8% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -247.8% | |
| Return on Assets (ROA) | -22.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$32M |
| Free Cash Flow | -$32M |
| Total Debt | $15M |
| Debt-to-Equity | 1699.1 |
| Current Ratio | 1.1 |
| Total Assets | $114M |
Price & Trading
| Last Close | $0.09 |
| 50-Day MA | $0.70 |
| 200-Day MA | $1.73 |
| Avg Volume | 67.2M |
| Beta | 1.3 |
|
52-Week Range
$0.08
| |
About Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Quince Therapeutics, Inc. (QNCX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Quince Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Quince Therapeutics, Inc.'s debt ratio?
Quince Therapeutics, Inc.'s debt ratio is 260.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 12.9%.
What are Quince Therapeutics, Inc.'s key financial metrics?
Quince Therapeutics, Inc. has a market capitalization of $5M. Return on equity stands at -247.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.